Based on the Swiss Pediatric Oncology Group (SPOG) cancer registry data during 1981-1991, a high average incidence of 8 new NHL per million children younger than 15 years per year was found.
Of 162 children with NHL registered in 1976-1991,120 were study patients, i.e., officially registered and treated according to SPOG or Pediatric Oncology Group (POG) protocols, while 42 were non-study patients, i.e., patients not officially enrolled on protocols.
Overall, 91 of 120 (76%) study patients re mained alive.
Seventy-nine study patients were treated according to older SPOG protocols, and 53 (67%) of these survived, while 38 of 41 (93%) study patients treated according to never POG protocols remained alive (P=0.0068).
Only 22 (52%) of the 42 non-study patients survived (P=0.0001).
There was no improvement if the survival of non-study patients before and since 1986 was compared.
Population-based treatment results in Switzerland were similar to those in the United Kingdom.
They provided an important base for the development of future treatment strategies.
Mots-clés Pascal : Lymphome non hodgkinien, Enfant, Homme, Préadolescent, Incidence, Pronostic, Survie, Epidémiologie, Traitement, Résultat, Suisse, Europe, Hémopathie maligne, Lymphoprolifératif syndrome
Mots-clés Pascal anglais : Non Hodgkin lymphoma, Child, Human, Preadolescent, Incidence, Prognosis, Survival, Epidemiology, Treatment, Result, Switzerland, Europe, Malignant hemopathy, Lymphoproliferative syndrome
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0278750
Code Inist : 002B19B. Création : 01/03/1996.